Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The ECJ's Ruling in the Generics Case: A Muddying of the Waters on the Interaction between the Basic Pharmaceutical Legislation and the SPC Regulation?

This article was originally published in SRA

Executive Summary

The strict application by the European Court of Justice of the law on generic approvals in the case of Generics (UK) Ltd v The Licensing Authority (acting via the Medicines and Healthcare products Regulatory Agency)1 is a victory for the innovative pharmaceutical industry. Following the ECJ’s ruling, a product that was initially granted a marketing authorisation under national rules which was never updated to meet current Community legislative requirements cannot be used as a “reference medicinal product” for the approval of a generic version containing the same active substance.

Advertisement
Advertisement
UsernamePublicRestriction

Register

PS114470

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel